2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Molecular Testing, Clinical Procedures, Treatment Considerations, Combination Therapy, Biological Therapies, Transplantation, Immunotherapy, Adverse Events, Biological Processes, Genomics, Hematopoiesis, Clinical Practice (Health Services and Quality), Practice Models, Diseases, Bleeding and Clotting, Thrombocytopenias, Bone Marrow Failure Syndromes, Aplastic Anemia, Hemoglobinopathies, Immunology, Immunodeficiency, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Aggressive Lymphoma, Research, AML, MDS, MPN, Clinical Research, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric
PAPER

2527 Clinical characteristics and transplant outcomes of patients with CHEK2 variants in hematologic malignancies: A single-center experience

Rick Y. Lin, MD, Sunmin Park, MD PhD2, Ni-Chun Tsai3, Dongyun Yang, PhD4, Sandra Dreike5, Salman Otoukesh, MD6, Hoda Pourhassan, MD7, Tamer Othman, MD8, Amanda Blackmon, DO9, Idoroenyi Amanam, MD10, Brian John Ball, MD, MS11, Paul Koller, MD12, Vaibhav Agrawal, MD13, Karamjeet Singh Sandhu, MD14, Samer K. Khaled, MD15, Ahmed Aribi, MD16, Ibrahim Aldoss, MD17, Haris Ali, MD18, Vinod Pullarkat, MD19, Andrew Artz, MD,MS20, Anthony Selwyn Stein, MD21, Pamela S. Becker, MD, PhD22, Stephen J. Forman, MD23, Guido Marcucci, MD24, Monzr M. M Al Malki, MD25, Ryotaro Nakamura, MD26, Michelle Afkhami27, Amandeep Salhotra, MD28
1 City of Hope, Duarte, United States
2 City of Hope, Duarte, California, United States
3 City of Hope, Duarte, California, United States
4 City of Hope, Duarte, California, United States
5 City of Hope, Duarte, California, United States
6 City of Hope, Duarte, California, United States
7 City of Hope, Duarte, California, United States
8 City of Hope, Duarte, California, United States
9 City of Hope, Duarte, California, United States
10 City of Hope, Duarte, California, United States
11 City of Hope, Duarte, California, United States
12 City of Hope, Duarte, California, United States
13 City of Hope, Duarte, California, United States
14 City of Hope, Duarte, California, United States
15 City of Hope, Duarte, California, United States
16 City of Hope, Duarte, California, United States
17 City of Hope, Duarte, California, United States
18 City of Hope, Duarte, California, United States
19 City of Hope, Duarte, California, United States
20 City of Hope, Duarte, California, United States
21 City of Hope, Duarte, California, United States
22 City of Hope, Duarte, California, United States
23 City of Hope, Duarte, California, United States
24 City of Hope, Duarte, California, United States
25 City of Hope, Duarte, California, United States
26 City of Hope, Duarte, California, United States
27 City of Hope, Duarte, California, United States
28 City of Hope, Duarte, California, United States

Background

CHEK2 encodes a cell-cycle checkpoint kinase involved in DNA damage repair and pathogenic variants are associated with an increased risk of solid tumors and hematologic malignancy. CHEK2 variants are increasingly being recognized in hematologic neoplasms, and their impact on outcomes after allogeneic hematopoietic cell transplant (HCT) need to be better defined. We describe the clinical characteristics and HCT outcomes of patients with CHEK2 variants at a single institution in United States.  

Methods

We retrospectively identified patients with hematologic malignancies with pathogenic or likely pathogenic (P/LP) CHEK2 variants with variant allele frequency (VAF) of 35-60% detected on somatic next-generation sequencing of the full exon region of the gene between March 2022 to June 2025. Overall survival (OS) and relapse-free survival (RFS) were estimated using Kaplan-Meier method and non-relapse mortality (NRM) by cumulative incidence with competing risks. Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) patients were further characterized by co-mutations, cytogenetics, ELN 2022 (AML) or IPSS-M (MDS), and pre-transplant measurable residual disease (MRD).

Results

27 patients were identified with a median age of 64 years (range: 21-83), 67% were male, and 89% were White. Median CHEK2 VAF was 47% (range: 38-53). Missense variants predominated (67%), followed by frameshift (22%), and nonsense (11%) mutations. The most common variants were c.470T>C (p.I157T; n=8, 30%), c.1100delC (p.T367Mfs*15; n=5, 19%), and c.1283C>T (p.S428F; n=4, 15%). Three patients (11%; 1 transplanted, 2 non-transplanted) had prior solid malignancy, two of whom developed therapy-related AML/MDS and one with confirmed germline testing for CHEK2. The most frequent co-mutations were ASXL1 (n=7, 26%, median VAF 32%), TET2 (n=6, 22%, median VAF 40%), DNMT3A (n=5, 19%, median VAF 39%), NRAS (n=5, 19%, median VAF 32%), followed by FLT3, JAK2, RUNX1. Diagnoses included AML (n=14), MDS (n=8), MPN (n=4), and T-lymphoblastic lymphoma (T-LBL, n=1). Among AML patients, ELN 2022 risk was favorable in 7% (n=1), intermediate in 43% (n=6), and adverse in 50% (n=7). Among the MDS patients, IPSS-M risk was Very High in 4, Moderate-Low in 3, and Low in 1.

Of the 27 patients, 19 (70%) underwent HCT with a median time of 9.2 months (range: 4.4-303.3) from diagnosis to HCT for AML (n=9), MDS (n=5), MPN (n=4), or T-LBL (n=1). Donors were matched related (n=3), unrelated (n=13) or haploidentical (n=3), using myeloablative (n=7) or reduced intensity (n=12) conditioning. GVHD prophylaxis consisted of tacrolimus/sirolimus (63%), post-transplant cyclophosphamide-based (32%), or other (5%). The median HCT-CI was 3 (range 0-11), and median Karnofsky performance status was 90 (range 70-100). Disease risk index was intermediate in 12 (63%), high in 6 (32%), and very high in 1 (5%). Of 9 AML patients transplanted, 7 (78%) received intensive induction and 2 (22%) received hypomethylating agent plus venetoclax. 4 patients (44%) achieved MRD- CR.

Neutrophil engraftment occurred in all patients (median: 17 days, range: 10-77), and platelet engraftment occurred in 95% patients at median time of 26.5 days (range: 6-147). Acute GVHD developed in 68% of patients, including grade III-IV acute GVHD in 16%. Chronic GVHD occurred in 58% (extensive disease: 53%). With a median follow-up of 30.2 months post HCT (range: 1.7-69), the estimated 24-month OS, RFS, and NRM were 67% (95% confidence interval [CI] 48.1-92.4%), 67% (95% CI 48.1-92.4%), and 11.1% (0-26.1%), respectively. Among related donor transplants, one sibling donor was subsequently confirmed to have the same germline CHEK2 mutation. To date, there is no known secondary solid tumors that developed after HCT among the 12 long-term HCT survivors.

Conclusion                                                       

Patients with P/LP CHEK2 variants undergoing HCT demonstrated reliable engraftment, acceptable acute GVHD rates, and low NRM. Persistence of CHEK2 variants after related donor HCT in one patient highlights the potential for donor-derived familial variants and underscores the importance of considering inherited predisposition during donor evaluation. Larger studies incorporating systematic germline testing are needed to define the prognostic and biologic significance of CHEK2 variants in hematologic malignancies and secondary cancer risk in HCT survivors.

Rick Y. Lin, MD: No relevant conflicts of interest to declare.